HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBD Product Sales Help Drive Tilray In 'Early Days' Of Global Cannabis Market

Executive Summary

"We're in the first inning of the development of this global industry," says Tilray CEO Brendan Kennedy. Hemp and cannabis product firms' opportunities with retailers should grow beyond number of stores selling products to also offering cannabinoids in addition to CBD.

You may also be interested in...



With Another Warning, FDA Pledges Report On CBD Use In Non-drug Products

CBD claim warning comes as FDA reviews more than 4,200 comments on its initiative to determine whether to open regulatory paths for firms to market non-drug products containing hemp- or cannabis-derived ingredients. From Deputy Commissioner Abernethy statement included in announcement about warning, it appears agency is getting message industry trade groups stated in comments that enforcement over non-drug products containing CBD cannot wait.

Continuing FDA Regulation Doesn't Dampen Cannabis Investment Enthusiasm

Anheuser-Busch's parent firm partners with Canadian firm Tilray, which makes and distributes cannabis supplements as well as dried cannabis, to research non-alcohol beverages containing tetrahydrocannabinol and cannabidiol.Similar moves by other firms entering the cannabis product market and mounting investments by US firms already in the space follow Congress' passage of the latest farm bill with a provision that substantially changes federal regulations for production and marketing of hemp.

Sandoz comments on Tilray

Sandoz Canada’s proposed entry into the medical cannabis space through its recent strategic alliance agreement with local producer Tilray broadly “complements its portfolio”, and “demonstrates again that the patient is at the heart of our work”, the Novartis affiliate has told Generics bulletin.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel